近日,云序生物助力郑州大学第一附属医院薛文华、任志刚、孙冉冉等在Advanced Science(IF=14.3)发表了题为“YBX1 Promotes Esophageal Squamous Cell Carcinoma Progression via m5C-Dependent SMOX mRNA Stabilization”的研究成果。该研究发现YBX1促进ESCC细胞的增殖和转移,并且阐明了在ESCC发展中,m5C介导的癌基因激活的新...
相关研究成果于2024年6月6日以“NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation”为题发表在《Breast Cancer Research》(乳腺癌研究)期刊。 标题:NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through ...
相关研究成果于2024年6月6日以“NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation”为题发表在《Breast Cancer Research》(乳腺癌研究)期刊。 标题:NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through ...
相关研究成果于2024年6月6日以“NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation”为题发表在《Breast Cancer Research》(乳腺癌研究)期刊。 标题:NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through ...
通过RNA测序(RNA-seq)和单碱基分辨率的m5C甲基化测序(RNA-BisSeq)筛选了BC中的m5C修饰靶标HGH1。并利用甲基化RNA免疫沉淀-qPCR(MeRIP-qPCR)和RNA结合蛋白免疫沉淀-qPCR(RIP-qPCR)鉴定了甲基化分子NSUN2和YBX1通过m5C修饰特异识别并结合HGH1。此外,研究还使用蛋白组学、共免疫沉淀(co-IP)和核糖体测序(Ribo-Seq...
研究结果表明,作为主要的m5C甲基化酶,NSUN2在BC中异常高表达,并提高了RNA m5C的整体水平。而敲低NSUN2表达可以在体外和体内抑制BC进展。结合RNA-seq和RNA-BisSeq分析鉴定出HGH1作为异常m5C修饰的潜在靶标。研究阐明了NSUN2如何通过m5C修饰调控HGH1表达的机制,这一过程包括与YBX1蛋白互作,共同影响mRNA稳定性和蛋白...
研究结果表明,作为主要的m5C甲基化酶,NSUN2在BC中异常高表达,并提高了RNA m5C的整体水平。而敲低NSUN2表达可以在体外和体内抑制BC进展。结合RNA-seq和RNA-BisSeq分析鉴定出HGH1作为异常m5C修饰的潜在靶标。研究阐明了NSUN2如何通过m5C修饰调控HGH1表达的机制,这一过程包括与YBX1蛋白互作,共同影响mRNA稳定性和蛋白...
YBX1以m5c依赖的方式促进H型血管依赖的骨形成 期刊名称:JCI insight 期刊IF:8.0 项目材料:人脐静脉内皮细胞HUVEC 爱基百客提供技术服务:CLIP-Seq 合作单位:内分泌学研究中心 Title(E):YBX1 promotes type H vessel–dependent bone formation in an m5C-dependent manner...
研究对象:5-Methylcytosine (m5C), NSUN2, E2F1, YBX1, and ovarian cancer;期刊:Experimental & Molecular Medicine;影响因子:12.7998;合作单位:重庆医科大学第三附属医院;发表时间:2024年4月 摘要 5-Methylcytosine (m5C) is a common RNA modification that modulates gene expression at the posttranscriptional ...
4a, b). Furthermore, we found that YBX1 expression remained stable in all (4/4) NSCLC patients with intrinsic resistance after gefitinib treatment using immunohistochemistry analysis (Fig. 4c, d). Thus, our data suggested that gefitinib treatment failed to down-regulate m5C reader YBX1 in ...